Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 5/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.40 |
| ▸ | KDR | P35968 | 6/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2446434 | 0.82 | NR1H2 (0.55) | NR1H2KDRROCK1MAPK14PARP1 | |
| SCHEMBL1683479 | 0.79 | NR1H2 (0.76) | NR1H2KDRROCK1PARP1 | |
| SCHEMBL4048440 | 0.79 | NR1H2 (0.67) | NR1H2EGFRERBB2KDRKDM4E | |
| SCHEMBL1728862 | 0.76 | NR1H2 (0.64) | NR1H2EGFRERBB2KDRKDM4E | |
| SCHEMBL1730410 | 0.75 | NR1H2 (0.73) | NR1H2KDRMAPK14KDM4EGAA | |
| SCHEMBL14110568 | 0.74 | NR1H2 (0.69) | NR1H2EGFRERBB2KDRKDM4E | |
| SCHEMBL1730673 | 0.74 | EGFR (0.50) | EGFRERBB2KDRMAPK14 | |
| SCHEMBL16646776 | 0.69 | NR1H2 (0.66) | NR1H2KDM4EGAA | |
| SCHEMBL2447815 | 0.69 | NR1H2 (0.52) | NR1H2KDRROCK1BRD4KDM4E | |
| SCHEMBL12728715 | 0.69 | NR1H2 (0.52) | NR1H2KDRROCK1BRD4MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569937-B1 | C-6 MODIFIED INDAZOLYLPYRROLOTRIAZINES | BRISTOL MYERS SQUIBB CO (US) | 2011-11-23 | — | — | EP | disclosed |
| EP-1569937-A4 | C-6 MODIFIED INDAZOLYLPYRROLOTRIAZINES | BRISTOL MYERS SQUIBB CO (US) | 2007-08-08 | — | — | EP | disclosed |
| US-7148220-B2 | C-6 modified indazolylpyrrolotriazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-12 | — | — | US | disclosed |
| US-20050222153-A1 | C-6 modified indazolylpyrrolotriazines | VITE GREGORY D | 2005-10-06 | — | — | US | disclosed |
| EP-1569937-A2 | C-6 MODIFIED INDAZOLYLPYRROLOTRIAZINES | Bristol-Myers Squibb Company (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6916815-B2 | C-6 modified indazolylpyrrolotriazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-12 | — | — | US | disclosed |
| US-20040142931-A1 | C-6 modified indazolylpyrrolotriazines | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004054514-A2 | C-6 MODIFIED INDAZOLYLPYRROLOTRIAZINES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222153-A1 | C-6 modified indazolylpyrrolotriazines | ERBB2, ERBB4, EGFR | NR1H2 2904/4885EGFR 3/4885ERBB2 1/4885 |
| US-20040142931-A1 | C-6 modified indazolylpyrrolotriazines | ERBB2, ERBB4, EGFR | NR1H2 2767/4885EGFR 3/4885ERBB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.